Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Colonic cancer. Adjuvant therapy: the Italian experience].
Cascinu S, Salvagni S, Camisa R, Gasparro D, Biscari L, Pucci F, Leonardi F, Franciosi V. Cascinu S, et al. Among authors: pucci f. Tumori. 2001 Jan-Feb;87(1 Suppl 1):S83-4. Tumori. 2001. PMID: 11300038 Italian. No abstract available.
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodinò C, Zironi S, Bisagni G, Porrozzi S, Cognetti F, Di Costanzo F, Canaletti R, Ruggeri EM, Camisa R, Pucci F; Italian Oncology Group for Clinical Research. Cocconi G, et al. Among authors: pucci f. Ann Oncol. 2003 Aug;14(8):1258-63. doi: 10.1093/annonc/mdg329. Ann Oncol. 2003. PMID: 12881389 Free article. Clinical Trial.
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A. Cascinu S, et al. Among authors: pucci f. Br J Cancer. 2008 Jan 15;98(1):71-6. doi: 10.1038/sj.bjc.6604121. Epub 2007 Dec 4. Br J Cancer. 2008. PMID: 18059397 Free PMC article. Clinical Trial.
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group. Bajetta E, et al. Ann Oncol. 2014 Jul;25(7):1373-1378. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12. Ann Oncol. 2014. PMID: 24728035 Free article. Clinical Trial.
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.
Di Bartolomeo M, Raimondi A, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E, Aitini E, Spada F, Rosati G, Marchet A, Pucci F, Zaniboni A, Tamberi S, Pressiani T, Sanna G, Cantore M, Mosconi S, Bolzoni P, Pinto C, Landi L, Soto Parra HJ, Cavanna L, Corallo S, Martinetti A, Hembrough TA, Pietrantonio F. Di Bartolomeo M, et al. Among authors: pucci f. Tumori. 2021 Apr;107(2):150-159. doi: 10.1177/0300891620930803. Epub 2020 Jun 11. Tumori. 2021. PMID: 32522106 Clinical Trial.
174 results